Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

July 11, 2024

Company name: SBI RHEOS HIFUMI Inc.

Name of representative: Hideto Fujino, Representative Director,

Chairman, President, Group CEO

(Securities code: 165A; TSE Growth Market)

Inquiries: Jiro Iwata, Managing Director,

Group CAO

## Notice Concerning Balance of Assets Under Management as of the End of June 2024

The balance of investment trust management and investment advisory business at SBI RHEOS HIFUMI increased by JPY 33.5 billion to JPY 1,384.5 billion from the end of the previous two months. The balance of investment trust business and investment advisory business reached a record high at the end of the month.

(Unit: billions of yen)

	2023					2024						
	July	Aug.	Sept.	Oct.	Nov.	Dec.	Jan.	Feb.	Mar.	Apr.	May	June
Publicly-offered investment trusts (Direct sales)	208.1	207.9	206.0	199.4	210.4	208.6	220.0	231.5	240.9	235.9	238.6	244.5
Publicly-offered investment trusts (Indirect sales)	887.5	884.0	867.8	838.0	879.7	862.4	900.1	939.3	982.2	961.5	975.2	999.0
Privately-placed investment trusts	1.6	1.6	1.6	1.5	1.6	1.7	2.0	2.1	2.1	2.0	1.8	1.7
Investment trust total	1,097.3	1,093.6	1,075.6	1,039.0	1,091.8	1,072.8	1,122.2	1,173.1	1,225.3	1,199.5	1,215.8	1,245.2
Investment advisory total	124.3	123.2	120.7	115.7	124.8	127.4	132.6	138.7	143.5	135.6	135.1	139.2
Company total	1,221.6	1,216.8	1,196.3	1,154.7	1,216.6	1,200.2	1,254.9	1,311.8	1,368.8	1,335.2	1,351.0	1,384.5

## (Notes)

- The above balance of assets under management is the balance of assets entrusted to us by our subsidiary, Rheos Capital Works Inc.
  (hereinafter referred to as "Rheos Capital Works"), a subsidiary of the Company. These assets are not directly held by the Group (SBI RHEOS HIFUMI Inc.).
- The above balance of assets under management will increase or decrease depending on changes in investment performance and the establishment and cancellation of funds.
- 3. The figures at the end of June 2024 are preliminary figures based on internal data at the time of preparation and may not be the same as the final figures.

4. Publicly offered investment trusts (direct sales) refer to publicly offered investment trusts sold directly to customers who have opened accounts at Rheos Capital Works, while publicly offered investment trusts (indirect sales) refer to those sold through partner banks and securities companies. The product line-up of Rheos Capital Works is as follows.

		By sales channel						
		Publicly-offered investment trusts (Direct sales)	Publicly-offered investment trusts (Indirect sales)	Privately-placed investment trusts				
By investment asset	Domestic equity	Hifumi Microscope pro	Hifumi Microscope pro	Rheos Japan Small-cap Equity Fund (For Private Placement)				
	Domestic and foreign equity	Hifumi Fund	Hifumi Plus Fund Hifumi DC Fund* Marugoto Hifumi 100	-				
	Foreign equity	Hifumi World	Hifumi World Plus Hifumi World DC Fund*	-				
	Domestic and foreign asset composite Hifumi Light (Balanced fund)		Marugoto Hifumi 15 Marugoto Hifumi 50	Marugoto Hifumi 50 (For Qualified Institutional Investors only)				

<sup>\*</sup> Hifumi DC Fund and Hifumi World DC Fund are investment trusts that can only be invested in a defined contribution plan (iDeCo/Corporate DC).